Genomics (Burkhart & Sage, 2008; George et al, 2015) and transcriptomics (Chen et al, 2019) analysis of cancer patients reveal that RB1 alterations predict poor clinical outcomes, raising the need for targeted therapies. Here, RB1 is linked to cancer.